. Author manuscript; available in PMC: 2010 Dec 1.

Published in final edited form as: Nat Med. 2010 May 23;16(6):718–722. doi: 10.1038/nm.2155

Table 1. External validation of DsRed with the congenic marker CD45.1 by ex vivo flow cytometry.

CD45.1⁺ in DsRed⁺	Untreated	98.9%
population	CD154-specific mAb plus rapamycin	96.2%
DsRed⁺ in CD45.1⁺	Untreated	97.5%
population	CD154-specific mAb plus rapamycin	88.5%
CD45.1⁺ in DsRed⁻	Untreated	2.4%
population	CD154-specific mAb plus rapamycin	8.3%
DsRed⁺ in CD45.1⁻	Untreated	1.1%
population	CD154-specific mAb plus rapamycin	2.6%

The correlation of the CD45.1 congenic marker with DsRed was calculated from spleen samples from the untreated mice and mice treated with CD154-specific mAb plus rapamycin on week 2 after transplantation by ex vivo flow cytometry on the basis of the percentage of CD4⁺CD45.1⁺ cells in the CD4⁺DsRed⁺ population and on the percentage of CD4⁺DsRed⁺ cells in the CD4⁺CD45.1⁺ population. False positives were calculated as the percentages of CD4⁺CD45.1⁺ cells in the CD4⁺DsRed⁻ population and DsRed⁺ cells in the CD4⁺CD45.1⁻ population.